Heron Therapeutics Stock Earnings Reports

Heron reported Q1 2026 net product sales of $34.7 million, with sequential recovery in March (> $15M) after severe winter-weather disruptions and typical seasonal headwinds in January. Despite the quarter coming in modestly below plan, management reiterated full-year 2026 guidance: net product sales $173M–$183M and adjusted EBITDA $10M–$20M. Commercial performance highlights: ZYNRELEF demand units grew 22% year-over-year, supported by the IGNITE program (now expanded into IGNITE 2.0 covering 3,109 accounts, +38%) and improved reimbursement (permanent J-code and NOPAIN framework); APONVIE demand units grew 68% year-over-year, has a permanent J-code effective April 1, is included in the 5th consensus PONV guidelines (A1 evidence rating, named specifically), and will benefit from a dedicated aprepitant sales force expansion in Q3; CINVANTI remained resilient with a stable ~25% market share in the NK1 category and a near-term pipeline of new formulary wins (~$10M annualized potential) from the REIGNITE program. Gross margin was 69% this quarter, pressured by higher-cost secondary CINVANTI manufacturing inventory that will be consumed over the next two quarters; management expects gross margins to normalize to mid-70% range thereafter. The company is moving forward with commercial expansions (ZYNRELEF and aprepitant-focused sales forces in Q3) and development progress on a ZYNRELEF prefilled syringe (on track for 12-month stability data in Q1 2027). Management emphasized that the quarter’s softness was external and temporary (weather/seasonality), that underlying demand and strategic drivers remain intact, and that cost discipline and margin normalization should drive adjusted EBITDA back to positive in 2026.